Patent classifications
C07D221/06
N-hydroxyethyl didehydroazapodophyllotoxins as GBP1 inhibitors and methods of overcoming treatment resistance in cancer
Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.
N-hydroxyethyl didehydroazapodophyllotoxins as GBP1 inhibitors and methods of overcoming treatment resistance in cancer
Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.
Organic electroluminescence device
The present invention relates to an electroluminescence device having high luminous efficiency (for example, external quantum efficiency) and high durability and causing little chromaticity shift after device deterioration. The present invention also relates to an organic electroluminescence device material comprising a substrate having thereon a pair of electrode and at least one organic layer between the electrodes, the organic layer containing a light emitting layer, wherein the light emitting layer contains a metal complex having a group represented by formula (I). ##STR00001##
Organic electroluminescence device
The present invention relates to an electroluminescence device having high luminous efficiency (for example, external quantum efficiency) and high durability and causing little chromaticity shift after device deterioration. The present invention also relates to an organic electroluminescence device material comprising a substrate having thereon a pair of electrode and at least one organic layer between the electrodes, the organic layer containing a light emitting layer, wherein the light emitting layer contains a metal complex having a group represented by formula (I). ##STR00001##
HYDROGENATION CATALYST FOR USE IN HYDROGENATING AMIDE COMPOUND AND METHOD FOR PRODUCING AMINE COMPOUND USING SAME
Provided is a hydrogenation catalyst for an amide compound, containing hydroxyapatite and platinum and vanadium that are fixed on the hydroxyapatite, 15 to 80% of the surface of the platinum being covered with vanadium. The hydrogenation catalyst can promote a reduction reaction in which an amide compound is converted into an amine compound, can be used under mild conditions, and has such durability that the catalyst can be repeatedly used while retaining a high activity.
OXYGEN SCAVENGERS, COMPOSITIONS COMPRISING THE SCAVENGERS, AND ARTICLES MADE FROM THE COMPOSITIONS
The disclosure relates to oxygen scavenging molecules, compositions, methods of making the compositions, articles prepared from the compositions, and methods of making the articles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
OXYGEN SCAVENGERS, COMPOSITIONS COMPRISING THE SCAVENGERS, AND ARTICLES MADE FROM THE COMPOSITIONS
The disclosure relates to oxygen scavenging molecules, compositions, methods of making the compositions, articles prepared from the compositions, and methods of making the articles. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1
The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.
INHIBITORS OF KIDNEY-TYPE GLUTAMINASE, GLS-1
The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.
Quinolines, Polyquinolines, Molecular Segments of Fullerenes and Graphene Nanoribbons, and Graphene Nanoribbons and Methods of Their Synthesis
Quinolines, polyquinolines, polybenzoquinolines, molecular segments of fullerenes and graphene nanoribbons, and graphene nanoribbons and processes for producing such materials are provided. The processes utilize a form of an aza-Diels-Alder (Povarov) reaction to first form quinolines and/or polyquinolines. In some such embodiments polyquinolines thus produced are used to form graphene nanoribbon precursors, and molecular segments and graphene nanoribbons. In many such embodiments the graphene nanoribbone precursors are formed from polybenzoquinolines.